Apr 29, 2020

A Prospective Phase 2 Trial of Daratumumab in Patients With Previously Treated Systemic Light-Chain Amyloidosis

Read more

Jun 03, 2018

Subcutaneous Daratumumab (DARA SC) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Patients (Pts) With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of Andromeda

Read more

Dec 31, 2017

Case Report: Treatment of Light-Chain Amyloidosis With Daratumumab Monotherapy in Two Patients

Read more

FDA Approves Subcutaneous Daratumumab Plus VCd for Newly Diagnosed Light-Chain Amyloidosis

Read more

Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (Daratumumab and Hyaluronidase-fihj) for the Treatment of Patients With Light Chain (AL) Amyloidosis

Read more

Daratumumab-Based Therapies in Patients With AL Amyloidosis

Read more

Ray Comenzo, MD, Discusses ANDROMEDA Trial in AL Amyloidosis Patients

Read more

Subscribe to